Homologous recombination deficiency advanced ovarian cancer research hub

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

This study looks at a new drug called niraparib to see if it can help women with advanced ovarian cancer stay well longer after their first round of chemotherapy. It compares niraparib to a dummy pill to find out how effective and safe it is.